Appendix 4D and Half Year Report to 31 December 2025

• Revenue up 54.5% to $305,820
• Loss down 15.1% to $2.17 million
• Signed multi-year distribution deal with Advanced Cosmeceuticals

Tissue Repair Ltd, a clinical-stage biopharmaceutical company developing advanced wound healing products, has reported its financial results for the half-year ended 31 December 2025. The company recorded a 54.5% increase in revenue to $305,820 and a 15.1% decrease in loss to $2,172,997 compared to the previous corresponding period. The Group's operating cash outflows for the half-year were $4,010,598, and the company reported closing cash of $8,294,468 at 31 December 2025. During the period, Tissue Repair signed a multi-year distribution agreement with Advanced Cosmeceuticals Pty Ltd, Australia's leading aesthetics and cosmeceutical skincare distributor, to launch its flagship product TR Pro+ across Australia and New Zealand. The agreement provides Tissue Repair the ability to market its product to over 2,500 clinics and a network that spans specialist skin clinics, dermatologists, plastic surgeons, pharmacies, and major online retailers. The company also provided updates on its ongoing research and development activities, including the development of TR Renew Serum, TR Med, TR S, and TR Ferrin. Additionally, the company is pursuing a U.S. 510(k) device regulatory pathway for its TR987 product, which is currently in Phase 3 clinical trials for the treatment of chronic wounds.

The company reported a 54.5% increase in revenue to $305,820 for the six-month period ended 31 December 2025.

Tissue Repair is in discussions with several Australian and global distributors across Asia, the Middle East, the USA, and Europe to expand the international distribution of its products. The company is also focused on rebuilding sales volumes in the Dermatology and Skin Cancer channels following the transition of aesthetic customers to the Advanced Cosmeceuticals distribution agreement.